Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

PurposeTo investigate whether progression-free survival (PFS) or time to progression (TTP) could be a valid surrogate endpoint for overall survival (OS) in patients with limited-stage small-cell lung cancer (LS-SCLC) receiving combined chemoradiotherapy.MethodsLiterature searching was performed in P...

Full description

Bibliographic Details
Main Authors: Yin Yang, Jianyang Wang, Wenqing Wang, Tao Zhang, Jingjing Zhao, Yu Wang, Yexiong Li, Luhua Wang, Nan Bi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Oncology
Subjects:
limited-stage small-cell lung cancer
surrogate endpoint
overall survival
progression-free survival
time to progression
chemoradiotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.810580/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.810580/full

Similar Items